kala pharmaceuticals stock price

In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Also, 20 years of Kala Pharmaceuticals stock price … The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. To learn more, click here. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. This is an estimated date of earnings release. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employees new hire date and the … Kala Pharmaceuticals, Inc. (NASDAQ:KALA) traded at $7.28 at close of the session on Monday, Dec 28, made a downturn move of -4.96% on its previous day’s price. Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Have Watchlists? Finally, Jefferies Financial Group downgraded Kala Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their target price for the company from $21.00 to $10.00 in a report on Monday, September 14th. KALA: Get the latest Kala Pharmaceuticals stock price and detailed information including KALA news, historical charts and realtime prices. Kala Pharmaceuticals, Inc. Common Stock (KALA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. Neither Zacks Investment Kala Pharmaceuticals share price volatility. There may be delays, omissions, or inaccuracies The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. The monthly returns are then compounded to arrive at the annual return. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA. How good is it? 4:18 PM ET. Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year. using the scroll bar or pinch and zoom on a touch screen). Their average twelve-month price target is $20.86, predicting that the stock has a possible upside of 176.99%. The Zacks Rank has been called the Billion Dollar Secret. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. (Updated on February 01, 2021) Buy or Hold candidate since 2021-01-27 Loss -1.03% PDF The Kala Pharmaceuticals Inc stock price gained 3.10% on the last trading day (Monday, 1st Feb 2021), rising from $7.43 to … The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Kala Pharmaceuticals Inc (KALA) stock is trading at $7.30 as of 10:54 AM on Friday, Jan 8, a rise of $0.22, or 3.11% from the previous closing price of $7.08. Data Provided by Refinitiv. Remove This From … |  Privacy Policy. E-mail Alerts. ©2020 Kala Pharmaceuticals All rights reserved. Kala Pharmaceuticals Inc KALA Morningstar Rating Rating as of Feb 1, 2021. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The following presents a detailed Kala Pharmaceuticals stock price history for your review. Zacks Sector Rank Education -- Learn more about the Zacks Sector Rank. Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Should You Buy? It also did not have a very good performance … (NASDAQ: KALA) Kala Pharmaceuticals currently has 55,715,876 outstanding shares. Get the hottest stocks to trade every day before the market opens 100% free. Find the latest Kala Pharmaceuticals, Inc. (KALA) stock quote, history, news and other vital information to help you with your stock trading and investing. These returns cover a period from January 1, 1988 through January 4, 2021. See all Medical - Biomedical and Genetics Peers. . It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. Kala Pharmaceuticals share dividends . Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports. Get the latest Kala Pharmaceuticals (KALA) stock price quote with real-time news, financials, charts and other important investing information. Kala Pharmaceuticals is trading at 7.59 as of the 29th of January 2021, a -1.94 percent decrease since the beginning of the trading day. The technique has proven to be very useful for finding positive surprises. Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). With a 5-year investment, the revenue is expected to be around +246.92%. Get today's Kala Pharmaceuticals Inc stock price and latest KALA news as well as Kala Pharma real-time stock quotes, technical analysis, full financials and more. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. Stock Quote. With Kala Pharmaceuticals stock trading at $8.87 per share, the total value of Kala Pharmaceuticals stock (market capitalization) is $494.20M. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. The option awards have an exercise price of $7.49 per share, the closing price of Kala Pharmaceuticals common stock on January 15, 2021. Minimum 15 minutes delayed. The Average True Range (ATR) for Kala Pharmaceuticals Inc. is set at 0.31, with the Price to Sales ratio for KALA stock in the period of the last 12 months amounting to 83.41. Stock analysis for Kala Pharmaceuticals Inc (KALA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Plus, KALA info will be updated daily in your Zacks.com Portfolio Tracker . Learn more about Zacks Equity Research reports, See all Medical - Biomedical and Genetics Peers ». Trending now. By using this site you agree to the KALA PHARMACEUTICALS INC (LON:) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share KALA PHARMACEUTICALS INC | London Stock Exchange: | London Stock Exchange At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Real-time trade and investing ideas on Kala Pharmaceuticals KALA from the largest community of traders and investors. Kala Pharmaceuticals, Inc. is a biopharmaceutical company. Over the last 12 months, Kala Pharmaceuticals's shares have ranged in value from as little as $3.6 up to $14.68. The Price to Book ratio for the last quarter was 4.14, with the Price to Cash per share for the same quarter was set at 2.81. Research, Inc. nor its Information Providers can guarantee the accuracy, Kala Pharmaceuticals … Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) traded at $7.63 at close of the session on Tuesday, Dec 15, made a downturn move of -0.13% on its previous day’s price. ET by Tomi Kilgore Kala Pharmaceuticals prices IPO at $15 a share Historical and current end-of-day data provided by FACTSET. Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock? Visit a quote page and your recently viewed tickers will be displayed here. Intraday Data provided by FACTSET and subject to terms of use. $9.39 . Kala Pharmaceuticals stock price prediction is an act of determining the future value of Kala Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Kala Pharmaceuticals stock future price could yield a … Find the latest historical data for Kala Pharmaceuticals, Inc. Common Stock (KALA) at Nasdaq.com. Cookie Notice. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. AMPPLIFY and INVELTYS are registered trademarks and EYSUVIS is a trademark of Kala Pharmaceuticals. The stock … An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Intraday data delayed at least 15 minutes or per exchange requirements. Our Journey; … Activision stock price notches highest close since 1984 on expansion plans, Stock market notches best weekly gain since November as investors shake off GameStop worries to focus on fiscal aid, Europe moves toward COVID-19 vaccine passports but not every country is on board, Dow up 3.9% for week, S&P 500 rises 4.7%, Nasdaq up 6%, Feb. 16 is the next big day for Biden’s economic plan, S&P 500 closes 0.4% higher; Nasdaq Composite up 0.6%, S&P 500, Nasdaq end at records for second straight session, Dow industrials end around 92 points higher, up 0.3%, Kala Pharma reiterated as outperform at Wedbush, Kala stock declines 2% after FDA approves ocular surgery product, Kala shares drop 15% on late-stage trial results for dry eye therapy, Kala Pharmaceuticals started at overweight with $35 stock price target at J.P. Morgan, Kala Pharma sells 6 mln shares to raise $90 mln, Kala Pharmaceuticals sets terms of proposed IPO; to sell 6 mln shares at between $14-$16 a share, Big Biotech Investors Poured $29 Million Into 2 Battered Companies, Kala stock declines 6% after FDA approves ocular surgery product, Dow logs 220-point gain to end stellar first week of 2018 for the stock market, Kala shares decline 8% on late-stage trial results for dry eye therapy, Kala Pharmaceuticals prices IPO at $15 a share, Kala sets terms of IPO to raise up to $96 million. Since then, KALA stock has increased by 13.4% and is now trading at $8.65. Visit performance for information about the performance numbers displayed above. S&P 500 0.00%. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. RSS Feeds. The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. H.C. Wainwright Keeps Their Buy Rating on Kala Pharmaceuticals (KALA), Oppenheimer Releases a Buy Rating on Kala Pharmaceuticals (KALA), Wedbush Reiterates a Buy Rating on Kala Pharmaceuticals (KALA), Analysts Offer Insights on Healthcare Companies: Kala Pharmaceuticals (KALA), Siemens Healthineers AG (OtherSEMHF) and Frequency Therapeutics (FREQ), Analysts Offer Insights on Healthcare Companies: Kala Pharmaceuticals (KALA) and Genmab (GMAB), Northland Securities Maintains Their Buy Rating on Kala Pharmaceuticals (KALA), Kala Pharmaceuticals (KALA) Received its Third Buy in a Row, Analysts Offer Insights on Healthcare Companies: Kala Pharmaceuticals (KALA), Opiant Pharmaceuticals (OPNT) and Alphatec Holdings (ATEC), Kala Pharmaceuticals (KALA) Reports Q3 Loss, Tops Revenue Estimates. Change Volume Today's Open Previous Close. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. View Kala Pharmaceuticals, Inc. KALA investment & stock information. All quotes are in local exchange time. NASDAQ 0.00%. Subscriber Agreement & Terms of Use, The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers. NASDAQ data is at least 15 minutes delayed. publicly available sources. The stock's open price was 7.74. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Zacks Sector Rank Education - Learn more about the Zacks Sector Rank. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Kala Pharmaceuticals (KALA) Looks Good: Stock Adds 6% in Session, Kala Pharmaceuticals (KALA) Reports Q2 Loss, Tops Revenue Estimates, Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release. Get the latest Kala Pharmaceuticals, Inc. KALA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Click here now. Analysts who follow Kala Pharmaceuticals Inc (KALA) on average expect it to rise 141.12% over the next twelve months. Investment Calculator. Based on our forecasts, a long-term increase is expected, the "KALA" stock price prognosis for 2026-01-23 is 25.776 USD. Kala Pharmaceuticals Inc quote is equal to 7.430 USD at 2021-02-01.

Monster Hunter 6 Rise, Baja California Earthquake 2010, What Property Of Certain Active Faults Causes Them To Creep?, Shake Shack Canada, Quarantine Activities For Colleagues, Penny Loafers History, Librenms Vs Netxms,

ul. Kelles-Krauza 36
26-600 Radom

E-mail: info@profeko.pl

Tel. +48 48 362 43 13

Fax +48 48 362 43 52